Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study

British Journal of Dermatology

Volumn 155, Issue 1, 2006, Pages 160-169

  Smith, C H ^a   Jackson, K ^a   Bashir, S J ^a   Perez, A ^a   Chew, A L ^a   Powell, A M ^a   Wain, M ^a   Barker, J N W N ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Centor and Schering Plough ^*  (Germany)

Author keywords

Biologics; Infliximab; Psoriasis

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; CELLULITIS; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEPATITIS; HUMAN; INJECTION SITE REACTION; MALE; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; QUALITY OF LIFE INDEX; SPLEEN ABSCESS; STATISTICAL ANALYSIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ABSCESS; ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; CARCINOMA, BASAL CELL; CARCINOMA, RENAL CELL; CELLULITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; LENTIGO; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RESPIRATORY TRACT INFECTIONS; SKIN NEOPLASMS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745021154     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07316.x     Document Type: Article

References (27)

1. Griffiths CE Clark CM Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000 4 : 1 125.
2. Sampogna F Sera F Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004 122 : 602 7.
3. Stern RS Nijsten T Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004 9 : 136 9.
4. Kirby B Richards HL Woo P et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001 45 : 72 6.
5. Choi J Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003 49 ( Suppl. 2 s57 61.
6. Rapp SR Feldman SR Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 7.
7. Chaudhari U Romano P Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 357 : 1842 7.
8. Gottlieb AB Evans R Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 42.
9. Roenigk H Auerbach R Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 38 : 478 85.
10. Reich K Nestle FO Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.
11. Chew A-L Bennett A Smith CH et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004 151 : 492 6.
12. Gottlieb AB Chaudhari U Mulcahy LD et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003 48 : 829 35.
13. Baert F Noman M Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 8.
14. Hanauer SB Wagner CL Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 53.
15. Cassano N Loconsole F Amoruso A et al. Infliximab monotherapy for refractory psoriasis: preliminary results. Int J Immunopathol Pharmacol 2004 17 : 373 80.
16. Gardam MA Keystone EC Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003 3 : 148 55.
17. Keane J Gershon S Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001 345 : 1098 104.
18. Lim WS Powell RJ Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med 2002 346 : 623 6.
19. Ledingham J Wilkinson C Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNFα treatments. Rheumatology (Oxford). 2005 44 : 10205 6.
20. Lee JH Slifman NR Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002 46 : 2565 70.
21. Slifman NR Gershon SK Lee JH et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003 48 : 319 24.
22. Wallis RS Broder MS Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004 38 : 1261 5.
23. Wallis RS Broder M Wong J Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004 39 : 1254 5.
24. Gelfand JM Berlin J Van Voorhees A Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003 139 : 1425 9.
25. Nijsten TEC Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003 121 : 252 8.
26. Boffetta P Gridley G Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001 117 : 1531 7.
27. Margolis DJ Bilker W Hennessy S et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001 137 : 778 83.